Oncoheroes Biosciences receives a second investment from The Andrew McDonough B+ Foundation

In October 2019, The Andrew McDonough B+ Foundation invested for the first time in Oncoheroes Biosciences, a biotech company advancing new therapies for childhood cancer. The B+ Foundation was the first childhood cancer non-profit to join Oncoheroes. Today, we are excited to announce that The B+ Foundation is investing again after assessing the company's progress during this period.

“Two years ago, we invested in a project led by two dads touched by childhood cancer with an undoubted passion and commitment. We knew they would put their soul and hearts into this ambitious project leading a group of life sciences industry experts,” stated Joe McDonough, co-founder and Executive Director of The Andrew McDonough B+ Foundation. “Today, we are glad to reinforce our support towards Oncoheroes after their demonstrated team's execution and the great milestones accomplished to date.”
The Andrew McDonough B+ Foundation honors the life of Andrew McDonough, who battled leukemia at the age of 14. Since its inception in 2007, the B+ Foundation has funded over 150 critical, cutting-edge childhood cancer research grants and is the largest provider of financial assistance to families touched by this disease in the US.
“This second investment from the B+ Foundation is an important endorsement for Oncoheroes and continues to demonstrate that childhood cancer non-profits are willing to play a more active role in accelerating the development of new therapies,” said Ricardo Garcia, co-founder and CEO of Oncoheroes Biosciences. “Thanks, B+ Foundation, for continue backing this unique project.”